Potential of Targeting BDCA2 in Cutaneous Lupus Erythematosus Management

Cutaneous lupus erythematosus (CLE) is driven by a complex interplay of innate and adaptive immune dysregulation, with plasmacytoid dendritic cells (pDCs) occupying a central role in disease pathogenesis. Activated pDCs produce substantial quantities of type I interferon and other pro-inflammatory cytokines and chemokines that perpetuate skin inflammation, drive keratinocyte injury, and contribute to the irreversible tissue damage that defines the most severe presentations of the disease. For a patient population that has long been managed with broadly immunosuppressive agents carrying significant toxicity profiles, a therapy designed to interrupt this pathway at its source represents a meaningful mechanistic departure from the standard of care.

Litifilimab targets BDCA2, a receptor selectively expressed on pDCs. Binding of litifilimab to BDCA2 suppresses pDC activation and downstream production of type I interferon and associated inflammatory mediators, offering a targeted approach to interrupting the immunological cascade thought to underlie CLE pathology. The specificity of this mechanism is clinically relevant: by acting on pDCs rather than broadly suppressing immune function, litifilimab has the potential to attenuate disease-driving inflammation while preserving broader immune competence.

That mechanistic rationale is now supported by a pair of positive Phase 2 trials. In the phase 2 portion of the AMETHYST study, litifilimab demonstrated a statistically significant 11.8% higher rate of clear or almost clear skin versus placebo at Week 16 (14.7% vs 2.9%; 95% CI: 1.39, 22.27; P < .05), with separation from placebo observed as early as Week 4. At Week 24, 40.8% of litifilimab-treated participants achieved a CLASI-50 response compared with 21% receiving placebo, and 1 in 6 participants in the litifilimab group achieved a CLASI score of 0 to 3, indicating no or minimal disease activity, compared with none in the placebo group. These results are consistent with the earlier LILAC Phase 2 study and collectively represent the only investigational program with positive efficacy data across multiple CLE trials to date.¹

In this segment, Joseph Merola, MD, MMSc, and Victoria Werth, MD, examine how the mechanism of action of litifilimab maps onto the immunopathology of CLE, what the AMETHYST results reveal about the durability and depth of response, and what these findings may mean for patients who have exhausted current treatment options.

References

1. Drenkard C, Barbour KE, Greenlund KJ, Lim SS. The burden of living with cutaneous lupus erythematosus. Front Med (Lausanne). 2022;9:897987. doi:10.3389/fmed.2022.897987
2. Biogen Inc. Biogen announces second positive Phase 2 litifilimab trial in cutaneous lupus erythematosus at 2026 American Academy of Dermatology Annual Meeting, showing a significant reduction in skin disease activity. Published March 28, 2026. https://investors.biogen.com/news-releases/news-release-details/biogen-announces-second-positive-phase-2-litifilimab-trial